Cargando…
Evaluating Osteogenic Differentiation of Osteoblastic Precursors Upon Intermittent Administration of PTH/IGFBP7
Parathyroid hormone (PTH) 1–34 is the first anabolic agent approved for the treatment of osteoporosis. Preclinical evidence shows a potential association between PTH and osteosarcoma. The mechanisms mediating the bone- and neoplasm-forming effects of PTH remain incompleted understood, few studies on...
Autores principales: | Xia, Han, Tian, Yueyang, Lin, Yile, Huang, Qia, Xue, Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019492/ https://www.ncbi.nlm.nih.gov/pubmed/35462909 http://dx.doi.org/10.3389/fphar.2022.839035 |
Ejemplares similares
-
Effects of PTH on osteoblast bioenergetics in response to glucose
por: DeMambro, Victoria E., et al.
Publicado: (2023) -
Procalcitonin is expressed in osteoblasts and limits bone resorption through inhibition of macrophage migration during intermittent PTH treatment
por: Baranowsky, Anke, et al.
Publicado: (2022) -
HDAC4 integrates PTH and sympathetic signaling in osteoblasts
por: Obri, Arnaud, et al.
Publicado: (2014) -
Intermittent PTH administration improves alveolar bone formation in type 1 diabetic rats with periodontitis
por: Kim, Ji-Hye, et al.
Publicado: (2018) -
The role of intermittent PTH administration in conjunction with allogenic stem cell treatment to stimulate fracture healing
por: Osagie-Clouard, Liza, et al.
Publicado: (2021)